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Axotomised Retinal Ganglion Cells from Apoptosis in
Adult Rats
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Abstract
Severing the axons of retinal ganglion cells (RGC) by crushing the optic nerve (ONC) causes the majority of RGC to
degenerate and die, primarily by apoptosis. We showed recently that after ONC in adult rats, caspase-2 activation occurred
specifically in RGC while no localisation of caspase-3 was observed in ganglion cells but in cells of the inner nuclear layer. We
further showed that inhibition of caspase-2 using a single injection of stably modified siRNA to caspase-2 protected almost
all RGC from death at 7 days, offering significant protection for up to 1 month after ONC. In the present study, we confirmed
that cleaved caspase-2 was localised and activated in RGC (and occasional neurons in the inner nuclear layer), while TUNEL+
RGC were also observed after ONC. We then investigated if suppression of caspase-2 using serial intravitreal injections of the
pharmacological inhibitor z-VDVAD-fmk (z-VDVAD) protected RGC from death for 15 days after ONC. Treatment of eyes with
z-VDVAD suppressed cleaved caspase-2 activation by .85% at 3–4 days after ONC. Increasing concentrations of z-VDVAD
protected greater numbers of RGC from death at 15 days after ONC, up to a maximum of 60% using 4000 ng/ml of z-
VDVAD, compared to PBS treated controls. The 15-day treatment with 4000 ng/ml of z-VDVAD after ONC suppressed levels
of cleaved caspase-2 but no significant changes in levels of cleaved caspase-3, -6, -7 or -8 were detected. Although
suppression of caspase-2 protected 60% of RGC from death, RGC axon regeneration was not promoted. These results
suggest that caspase-2 specifically mediates death of RGC after ONC and that suppression of caspase-2 may be a useful
therapeutic strategy to enhance RGC survival not only after axotomy but also in diseases where RGC death occurs such as
glaucoma and optic neuritis.
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Introduction
Injury to the optic nerve (ON) triggers progressive death of
retinal ganglion cells (RGC), the severity of which is dependent
upon the type of lesion and its distance from the eye [1,2,3]. For
example, intraorbital ON transection and ON crush (ONC) both
trigger 70–75% RGC loss within 7 days after injury [4,5,6,7] and
by 28 days, 80–90% RGC are lost, primarily by apoptosis
[8,9,10]. RGC apoptosis, however, is recognised as a limiting
factor to the regenerative potential of RGC axons. Therefore,
treatments to block RGC apoptosis have been studied extensively.
For example, inhibition of apoptosis by neurotrophic factor
administration [11], overexpression of Bcl-2 [12,13] and inhibition
of caspase-1 and -3 [14,15] and caspase-6 and -8 [16] using
pharmacological inhibitors all reduced the number of dying RGC
after ON transection and ONC. To date, only caspase-6 and -8
inhibitors have yielded limited RGC axon regeneration after ON
axotomy [16].
Apoptosis is orchestrated by caspases, cysteine-rich proteases
capable of targeting proteins that play critical roles in DNA
replication [17,18], DNA repair [19], cell survival signalling [20]
and the regulation of proteins that control cytoskeletal re-
organisation and cellular disassembly [21,22]. There are two
groups of caspases: initiator (caspase-2, -8, -9, and -10) and effector
caspases (caspase-3, -6 and -7) the former are activated by either
death receptor activation, or the release of cytochrome-c from
mitochondria, which activate effector caspases through proteolytic
processing of pro-caspases, culminating in cleavage of structural
proteins and eventual death [23,24,25,26].
One of the most highly conserved caspases is caspase-2, which
acts as both an initiator and an executioner depending on the
apoptotic stimuli [27,28,29,30]. Caspase-2 deficient neurons are
resistant to apoptosis by b-amyloid [31,32] while activation of
caspase-2 mediates apoptosis of hippocampal neurons after
transient global ischemia [33]. Caspase-2 is also expressed in the
RGC of ischaemic retinae [34] and the neuroprotective effect of
brain-derived neurotrophic factor (BDNF) is associated with
reduced caspase-2 [35]. We have shown unequivocally that, 7
days after ONC, caspase-2 is specifically activated in RGC and
that inhibition of caspase-2 by stably-modified siRNA protects
98% of RGC from death at 7 days after ONC and significant
RGC protection lasted for at least 30 days [5,6,7]. Here, we report
that a serially injected cell permeable pharmacological inhibitor of
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caspase-2 protects 60% of RGC from apoptotic death 15 days
after ONC but does not promote RGC axon regeneration. Our
results suggest that caspase-2 is an important executioner molecule
in RGC apoptosis.
Materials and Methods
Ethics statement
This study was carried out in strict accordance to the Animals
Scientific Procedures Act, 1986 and all procedures were licensed
and approved by the UK Home Office. The protocols and
experiments were also approved by the University of Birmingham
Ethical Review Sub-Committee. Animals were kept in environ-
mentally controlled animal facilities at the University of Birming-
ham. All surgery was performed under inhalation anaesthesia
using 5% Isofluorane (IsoFlo, Abbott Animal Health, North
Chicago, IL, USA) induction and 2% for maintenance. Every
effort was made to minimise animal suffering.
ON crush (ONC)
The ON of adult female 200–250 g Spraque-Dawley rats
(Charles River, Margate, UK) was exposed through a supraorbital
approach and crushed bilaterally within the orbit, 2 mm from the
eye, using forceps as described previously [5,7,36,37,38,39].
Intravitreal injections
The cell membrane permeable caspase-2 inhibitor, z-V-D-
(OMe)-V-A-D(OMe)-fluromethylkeone (z-VDVAD) (R&D Sys-
tems, Abingdon, Oxford, UK), was dissolved in sterile DMSO
(Sigma, Poole, UK) and further diluted in sterile PBS before
intravitreal injection in a final volume of 5 ml. Control animals
(n = 6 rats/treatment (12 eyes/treatment)) were intravitreally
injected with PBS (containing the same diluted amount of DMSO
as z-VDVAD) (vehicle) at the same time-points as z-VDVAD,
whilst treated rats (n = 6 rats/treatment (12 eyes/treatment))
received either 400 ng/ml, 1000 ng/ml, 2000 ng/ml, 4000 ng/
ml or 5000 ng/ml of z-VDVAD immediately after ONC (day 0),
and intravitreal injections repeated at 4, 8 and 12 d after ONC.
The rationale for doses of 400 ng/ml and 4000 ng/ml were based
on previously published data using caspase-3 inhibitors [40].
Animals survived for 15 d, after which the retinae were dissected
out for retinal wholemounts and protein extraction for western
blotting, while whole eyes were removed for immunohistochem-
istry. None of the animals developed cataracts, confirming that the
lens had not been injured either during surgery or after subsequent
intravitreal injections.
Determining the optimal dosing regime
To determine the frequency of intravitreal z-VDVAD injec-
tions, we used the same dose of a pharmacological inhibitor to
caspase-3 and the same 3–4 d injection schedule after ONC,
reported by Kermer et al. (1998) [40] that caused RGC survival.
We therefore chose to intravitreally inject 4000 ng/ml immedi-
ately after ONC and killed animals at 2, 3 and 4 days by overdose
of CO2 (n= 3 rats/treatment (6 retinae/treatment)). Eyes were
enucleated, retinae harvested and snap frozen until required for
extraction of total proteins and western blotting as described later.
Retinal wholemounts
At 13 d after ONC, 2 ml of 4% FluoroGold (FG, Cambridge
Bioscience, Cambridge, UK), were prepared from a solid stock
and injected into the proximal ON segment mid-way between the
lamina cribrosa and the site of ONC. Animals were killed and eyes
were enucleated 48 h later and retinae were immersion-fixed in
4% formaldehyde (TAAB Laboratories, Aldermaston, UK) for
30 min, and flattened onto a Superfrost Plus microscope slides
(VWR International, Lutterworth, UK), after dividing the retinae
with 4 equidistant radial cuts to give 4 equally sized quadrants
attached together at the optic disc. Retinal wholemounts were
dried onto glass slides and mounted in Vectamount (Vector
Laboratories, Peterborough, UK). Samples were randomised and
blinded by a second investigator and photographs were captured
using a Zeiss fluorescent microscope equipped with a digital
camera in Axiovision 4 (all from Zeiss, Hertfordshire, UK). The
number of FG-labelled RGC was counted using automated
particle counting software in ImagePro Version 6.0 (Media
Cybernetics, Bethesda, USA) from photographs of 12 rectangular
areas (0.3660.24 mm), 3 from each quadrant, placed at radial
distances from the centre of the optic disc of the inner (1/6
eccentricity), midperiphery (1/2 eccentricity) or outer retina (5/6
eccentricity). RGC densities were summed together and averaged
over the entire retina and expressed as mean RGC densities/mm2
for each treatment (n = 6 rats/treatment (12 retinae/treatment)).
Tissue preparation and sectioning
After intracardiac perfusion with 4% formaldehyde, eyes and
ON were removed, immersion-fixed in 4% formaldehyde (TAAB)
for 2 h, washed for 10 min in 10 mM phosphate buffered saline
(PBS), and immersed in 10% and 20% sucrose (Sigma) each for
2 h and finally immersed in 30% sucrose overnight. Eyes and ON
were embedded in OCT mounting medium (Raymond A Lamb
Ltd) and 15 mm thick parasaggital sections of eyes and longitudinal
sections of ON were cut on a cryostat (Bright Instruments,
Huntingdon, UK), adhered onto glass slides and stored at 220uC
until required.
Immunohistochemistry
Double immunohistochemistry for cleaved caspase-2 (C-
CASP2) and bIII-tubulin was performed on sections of retina as
described by us previously [7]. Briefly, sections were washed in
PBS, non-specific binding blocked with PBS containing 3% BSA
and 0.05% Tween 20 for 20 min before incubation with rabbit
anti-C-CASP2 (Abcam, Cambridge, UK; 1:200 dilution) and
monoclonal anti-bIII-tubulin (Sigma, Poole, UK; 1:200 dilution)
primary antibodies overnight at 4uC. Sections were then washed in
63 changes of PBS, incubated with appropriate Alexa Fluor 488
and Texas Red-labelled secondary antibodies for 1 h at room
temperature, washed, mounted using Vectashield mounting
medium with DAPI (Vector Laboratories) and examined under
an Axioplan-2 epi-fluorescent microscope (Zeiss).
GAP-43 immunohistochemistry was performed on ON sections
(n = 9 rats/treatment; (i.e. 18 ON)) to detect RGC axon
regeneration at 15 d after ONC using a sheep polyclonal anti-
GAP-43 antibody (donated by Professor Larry Benowitz, Harvard
Medical School, Boston, USA) as described previously [39].
Protein extraction and Western blotting
At 15 d after ONC, a total of 3 rats/treatment group were killed
and retinae (n = 3 rats/treatment (6 retinae/treatment)) were
pooled prior to protein extraction in cell lysis buffer and processed
for Western blotting as previously described [7]. Experiments were
then repeated62 using a further 3 rats/treatment/experiment and
retinae (n = 6 retinae/treatment/experiment) were again pooled
and proteins extracted prior to western blot analysis. Western blots
were probed overnight at 4uC with antibodies against: Goat anti-
human cleaved caspase-2 (directed against the p12 fragment) (C-
CASP2) and rabbit anti-human cleaved caspase-8 (p20 fragment)
(C-CASP8) (both from Santa Cruz Biotechnology, CA, USA);
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Rabbit anti-cleaved caspase-3 (C-CASP3), rabbit anti-cleaved
caspase-6 (C-CASP6) and rabbit anti-cleaved caspase-7 (C-
CASP7) (all from Cell Signalling Technology, Danvers, MA,
USA). Relevant bands were detected with an appropriate HRP-
labelled secondary antibody (GE Healthcare, Buckinghamshire,
UK) and detected using an enhanced chemiluminescence system
(ECL) (GE Healthcare).
Western blots were probed with a rabbit monoclonal antibody
to GAPDH (Cell Signalling Technology, Danvers, MA, USA) at
1:1000 dilution and used as a loading control. Blots were stripped
and re-probed as required.
Biotin-VAD-fmk trapping assay of active caspase
The caspase trapping assay which employs the bVAD (biotin-
Val-Ala-DL-Asp-fluoromethylketone (biotin-VAD-fmk)) probe is
the best way to determine whether caspases are active after a death
stimuli. bVAD is an irreversible pan-caspase inhibitor and binds
irreversibly to all activated caspases. Once bVAD binds irrevers-
ibly it inhibits that specific caspase and blocks downstream events,
and as the bVAD is biotinylated, it can be isolated on streptavidin
agarose along with any active caspases that are bound to it. We
therefore used the biotin-VAD-fmk assay was used to detect the
presence of active caspase-2 as described previously [28,41,42] but
with modifications for our in vivo experiments. Briefly, 200 nmol of
b-VAD-fmk (MP Biomedical, UK) was diluted in 5 ml of sterile
saline and intravitreally injected 24 hr prior to ONC (to capture
any caspases being activated by ONC) while control animals
received 5 ml of sterile saline prior to ONC. bVAD treated animals
were killed at 1, 4 and 7 d after ONC whilst control animals were
killed at 4 d (since our previous experiment demonstrated optimal
C-CASP2 immunohistochemistry at this time-point). Eyes were
enucleated and retinae were immediately homogenised in ice-cold
Figure 1. Caspase-2, TUNEL localisation in RGC and caspase trapping assay. (A) Immunohistochemistry to show the absence of C-CASP2
(red) reactivity in bIII-tubulin+ (green) RGC in intact controls, while 4 days after ONC the majority of bIII-tubulin+ RGC (green) were C-CASP2+ (red;
arrowheads). (B) bIII-tubulin+ RGC in intact controls were also negative for TUNEL staining while some TUNEL+ (arrowheads) RGC were present at 4 d
after ONC. Some RGC were also negative for TUNEL staining at 4 d after ONC (arrow). (C) Active CASP2 is induced by ONC and its levels increase over
the 7 d time period and (D) densitometry to quantify the relative CASP2 activity compared to controls. GCL= ganglion cell layer. Scale bars in A and
B=50 mm.
doi:10.1371/journal.pone.0053473.g001
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CHAPS buffer (150 mM KCl, 50 mM HEPES and 0.1% CHAPS
(pH 7.4)) supplemented with protease inhibitor cocktail (Sigma).
Samples were incubated on ice for 10 min prior to centrifugation
at 130006 g for 10 mins at 4uC and the supernatants were
collected and boiled for 5 min. Streptavidin-agarose beads were
then added to the boiled supernatant and incubated overnight at
4uC with constant agitation. Beads were spun at 75006 g for
5 min at 4uC, washed 65 in PBS, resuspended in 26 Laemmli
buffer and boiled for 5 min. The beads were centrifuged at
150006 g for 10 min, supernatant collected and supplemented
with 5% 2-mercaptoethanol and samples were resolved on 12%
SDS-PAGE gels and analysed by western blotting as described
above using an affinity purified goat polyclonal anti-C-CASP2
antibody (Santa Cruz Biotechnology). Blots were stripped and re-
probed with antibodies against total CASP-2 (Santa Cruz
Biotechnology) and GAPDH (Cell Signalling Technology).
Densitometry
Western blots were quantified by densitometry as described by
us previously [7,38,39]. Briefly, blots were scanned into Adobe
Photoshop and TIFF files were analysed in ScionImage (version
4.0.2, Scion Corp, Maryland, USA) using the built-in gel plotting
macros. The integrated density of each band in each lane was
calculated from 3 separate blots.
Statistical analysis
The significance of differences between sample means were
calculated using GraphPad Prism (GraphPad Software Inc.,
Version 4.0, CA, San Diego, USA) by one-way analysis of
variance (ANOVA) followed by post-hoc testing with Dunnett’s
method.
Results
ONC induced caspase-2 activation and TUNEL in RGC
We have previously shown that C-CASP2 is localised in
RGC within 5 hr after ONC and is present in a significant
number of RGC after 24 hr [7]. Here we confirmed by
immunohistochemistry that C-CASP2 was absent in bIII-
tubulin+ RGC in intact (uninjured) animals (Figure 1A), but
was specifically localised in RGC and present in abundant
numbers of RGC at 4 d after ONC (Fig. 1A). The localisation
of C-CASP2 paralleled the presence of TUNEL+ nuclei in
bIII-tubulin+ RGC in ONC animals (Figure 1B), indicating
RGC apoptosis. The b-VAD caspase trapping assay captured
increasing amounts of CASP2 activity and demonstrated 2-, 3-
and 6-fold higher levels of CASP2 at 1 d, 4 d and 7 d,
respectively, when compared to controls (Figure 1C and D).
Other caspases (e.g. CASP3 or CASP7 (data not shown)) were
not captured. These results demonstrate that CASP2 is
localised and specifically activated in RGC after ONC.
Determining the frequency of z-VDVAD administration
After ONC and immediate intravitreal injection of 4000 ng/
ml of z-VDVAD, western blotting detected reduced levels of
C-CASP2, of approximately 50% (P,0.0001, ANOVA), at 2 d
after ONC compared to ONC+vehicle treated eyes (Figure 2A
and B). The levels of C-CASP2 decreased significantly by
.85% at 3 days (P,0.0001, ANOVA), remaining significantly
low for 4 days (P,0.0001, ANOVA) but without further
reductions from day 3 (Figure 2A and B). Based on these
results, every 4th day was selected for repeated intravitreal
injections of z-VDVAD for the duration of the 15 d experi-
mental time period to minimise the number of intravitreal
injections required prior to harvesting of tissues.
z-VDVAD promoted RGC survival after ONC
To determine whether inhibition of caspase-2 protected
RGC from apoptosis for 15 d after ONC, we injected z-
VDVAD intravitreally every 4th day and compared results with
control vehicle treated eyes. Very few FG+ RGC were
observed in retinal wholemounts from ONC+vehicle injected
eyes (Figure 3A and G) compared to those treated with
increasing concentrations of z-VDVAD (400 ng/ml to
5000 ng/ml) (Figure 3B–F and G), where progressively more
FG+ RGC were present up to a concentration of 4000 ng/ml
(Figure 3E and G) (P,0.0001, ANOVA). There was no
increase in FG+ RGC using the highest concentration of z-
VDVAD (5000 ng/ml) (Figure 3F and G) compared to that
observed at 4000 ng/ml RGC (Figure 3E and G). No changes
in cell morphology, nor soma size were observed in retinal
wholemounts after treatment with z-VDVAD, with all RGC
morphology appearing healthy and as diverse soma sizes as
that observed in controls without z-VDVAD treatment
(Figure 3A–F: insets) The average density of FG+ RGC in
ONC+vehicle treated eyes were 293634 RGC/mm2
(Figure 3A). Intravitreal delivery of 400 ng/ml of z-VDVAD
increased RGC survival to 590656 RGC/mm2, while the
optimum concentration of 4000 ng/ml z-VDVAD increased
Figure 2. Determining the optimal z-VDVAD dosing regime. (A)
Representative western blot to show that 4000 ng/ml z-VDVAD
treatment caused optimal suppression of C-CASP2 (.80%) by 3 d after
ONC. (B) Densitometry confirmed 50% reduction of C-CASP2 by 2 d
after ONC+z-VDVAD treatment compared to ONC alone, which
increased to 80% at 3 d after ONC+z-VDVAD treatment with no further
reduction by 4 d. GAPDH was used as a loading control. n = 6 rats/
treatment (12 eyes/treatment).
doi:10.1371/journal.pone.0053473.g002
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survival to 1430630 RGC/mm2 (Figure 3G). Therefore,
4000 ng/ml of z-VDVAD protected 60% of RGC from death
after 15 d compared to uninjured, intact controls (Figure 3G).
z-VDVAD reduces caspase-2 activation in RGC of the
ganglion cell layer
We investigated if intravitreal z-VDVAD injection maintained
the suppression of cleaved caspase-2 (C-CASP2) in sections of
retinae by immunohistochemistry at 15 d. After ONC+vehicle
treatment (Figure 4A and B), C-CASP2 was localised in most
ganglion cells (GCL) and cells of the inner nuclear layer (INL).
However, treatment with 4000 ng/ml of z-VDVAD (Figure 4C
and D) almost completely suppressed C-CASP2 immunohisto-
chemistry. High power magnifications of the GCL confirmed C-
CASP2 immunolocalisation in cells of the GCL after ONC+ve-
hicle treatment (Figure 4E and F) while little or no immunoloca-
lisation for C-CASP2 was observed in the cells of the GCL of eyes
treated with 4000 ng/ml z-VDVAD (Figure 4G and H).
Co-localisation of C-CASP2 with bIII-tubulin+ confirmed that
bIII-tubulin+ RGC showed specific C-CASP2 activation in RGC
after ONC+vehicle (Figure 4I–K) but little or no C-CASP2
activation in bIII-tubulin+ RGC after treatment with 4000 ng/ml
z-VDVAD (Figure 4L–N).
Only C-CASP2 levels are suppressed by z-VDVAD
Using western blots of retinal lysates, we found that
ONC+vehicle treatment not only upregulated pro-caspase-2
(Pro-CASP2) (P,0.001, ANOVA) in the retina but also
significantly upregulated the levels of C-CASP2 (P,0.0001,
ANOVA), particularly the p12 fragment recognised by our
which our antibody, as detected by the relative band size
(Figure 5A) but also after quantification by densitometry
(Figure 5B). However, ONC+4000 ng/ml of z-VDVAD
treatment significantly reduced C-CASP2 and the integrated
density of the C-CASP2 p12 fragment (P,0.0001, ANOVA)
(Figure 5A and B).
Figure 3. Treatment with z-VDVAD protects RGC from death at 15 d after ONC. FG+ RGC in flat mounted retina and high power inserts
after (A) ONC+vehicle, (B) ONC+400 ng/ml z-VDVAD, (C) 1000 ng/ml and ONC+1000 ng/ml z-VDVAD, (D) ONC+2000 ng/ml z-VDVAD, (E)
ONC+4000 ng/ml z-VDVAD, (F) ONC+5000 ng/ml z-VDVAD at 15 d after ONC. (G) Quantitation of surviving RGC density (6SEM) at 15 d after ONC and
treatment with z-VDVAD. Scale bars in A–F= 50 mm, and in insets = 25 mm.
doi:10.1371/journal.pone.0053473.g003
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Since Pro-CASP2 can be activated by cleaved caspase-3 (C-
CASP3) we probed our western blots against antibodies to C-
CASP and detected the p17/19 processed fragment of C-
CASP3 (Figure 5A) which was upregulated after ONC+vehicle
treatment (P,0.001, ANOVA) (Figure 5A and C). However,
these raised levels of C-CASP3 p17/p19 fragment were
unaffected by 4000 ng/ml z-VDVAD treatment. We then
probed our blots with antibodies against cleaved caspase-6 (C-
CASP6), -7 (C-CASP7) and -8 (C-CASP8) to investigate if z-
VDVAD non-specifically attenuated other caspases implicated
in RGC survival after ONC and failed to observe any
significant changes after treatments in C-CASP3, C-CASP6,
C-CASP7, or C-CASP8 (Figure 5A–C).
Inhibition of caspase-2 does not promote RGC axon
regeneration after ONC
To investigate if suppression of caspase-2 by z-VDVAD
enhanced RGC axon regeneration, we stained longitudinal
sections of ON with antibodies against GAP-43 to detect
regenerating axons. In ONC+vehicle treated rats, there were
few surviving axons in the proximal ON segment between lesion
site and eye at 15 d while no axons extended across the lesion into
the distal ON segment (Figure 6A). However, in sections of ON
treated with ONC+4000 ng/ml z-VDVAD greater numbers of
GAP-43+ RGC axons were seen in the proximal ON segment,
reflecting RGC survival, but no axons traversed the crush site to
enter the distal ON segment (Figure 6B). Taken together, these
data showed that caspase-2 inhibition promotes significant RGC
survival but not axon regeneration.
Figure 4. C-CASP2 immunoreactivity after treatment with z-VDVAD. (A, B) C-CASP2 is highly up regulated in ONC+vehicle treated in the GCL
and INL cells. (C, D) C-CASP2 immunoreactivity (red) was barely detectable in the GCL after treatment with 4000 ng/ml z-VDVAD. (E–H) High power
magnification of the GCL showed C-CASP2 immunoreactivity (red) in RGC after ONC+vehicle treatment (arrowheads) whilst treatment with z-VDVAD
suppressed immunoreactivity in the GCL. Double immunohistochemistry showing that bIII-tubulin+ RGC (I) were also C-CASP2+ (J) (arrowheads) after
ONC+vehicle treatment while treatment with ONC+4000 ng/ml z-VDVAD suppressed C-CASP2 levels in RGC (L–N). GCL =ganglion cell layer,
INL = inner nuclear layer; ONL=outer nuclear layer. Scale bars in A–D, 100 mm, scale bars in E–N, 50 mm.
doi:10.1371/journal.pone.0053473.g004
z-VDVAD Rescues RGC from Death
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Discussion
The data presented in this study confirm our previous findings
that caspase-2 is an important regulator of RGC apoptosis induced
after ONC [7]. We report that caspase-2 is specifically activated in
RGC and that significant RGC survival is promoted after
pharmacological inhibition of caspase-2 with z-VDVAD, but no
RGC axon regeneration occurs. These results complement those
of our previous study with a gene silencing approach [7],
demonstrating that caspase-2 is a key orchestrator of RGC
apoptosis.
Caspase-mediated RGC apoptosis
Caspase-3, -6, -8 and -9 activities all play a role in RGC
apoptosis after ON injury [1,15,16]. Using inhibitors besides
caspase-2, RGC neuroprotection ranged from 30–60% at 15 d
after ONC [16,43,44], with caspase-8 inhibitors supporting the
survival of nearly 60% RGC compared to intact controls [16].
Inhibition of caspase-2 using a chemically stabilised siRNA at 7 d
after ONC rescued 98% RGC from apoptosis [7]. In the current
study, pharmacological inhibition of caspase-2 with repeated
delivery of z-VDVAD over a 15 d period after ONC protected
60% RGC from apoptosis, corroborating our earlier study that
caspase-2 is an important regulator of RGC apoptosis [7]. We
have not established the long-term efficacy of z-VDVAD on RGC
neuroprotection, however, the advantage of z-VDVAD is that it is
an already available, small molecule inhibitor that may be used
immediately in clinical trials. Our results are similar to those of
Monnier et al. (2011) [16] who reported similar levels of RGC
rescue at 14 d after ONC and ON transection with a similar
intravitreal delivery regime, using a caspase-8 and caspase-6
inhibitor, respectively.
Although caspase-3 inhibition rescued ,35% RGC from death
[15], we localised C-CASP3 not in RGC but in neurons of the
INL [7], suggesting that caspase-3 was not a direct regulator of
RGC apoptosis. In the current study, the observed elevated levels
of C-CASP3 after ONC were not attenuated by z-VDVAD,
suggesting that caspase-3 was not activated as a downstream
effector molecule by caspase-2. Moreover, C-CASP6, C-CASP7
and C-CASP8 levels were unchanged after ONC and were also
Figure 5. Western blot analysis after z-VDVAD treatment. (A) Pro-CASP2 levels rose after ONC and remained high even after treatment with
4000 ng/ml z-VDVAD. The level of the C-CASP2 p12 fragment also rose after ONC but was significantly decreased after treatment with z-VDVAD. (A)
and (B) Levels of Pro-CASP2 and C-CASP2 (p12) reflected these changes and showed that the C-CASP2 fragment was 40% lower in retinae treated
with 4000 ng/ml z-VDVAD than those treated with vehicle alone. C-CASP3 and C-CASP6 levels increased after ONC+vehicle treatment but these levels
remained unchanged after ONC+4000 ng/ml z-VDVAD treatment. C-CASP7 and C-CASP8 levels were much lower and did not change after
ONC+vehicle, or ONC+4000 ng/ml z-VDVAD treatments. (B) and (C) Densitometry reflected these observed changes in Pro-CASP2, C-CASP2, C-CASP3,
C-CASP6, C-CASP7 and C-CASP8. GAPDH was used as a loading control.
doi:10.1371/journal.pone.0053473.g005
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unaffected by z-VDVAD caspase-2 inhibitor suggesting that,
although caspase-3 and -7 can be inhibited by the VDVAD
substrates [45], C-CASP3 and C-CASP7 were not affected in this
instance. We therefore, attribute the RGC protective effect of z-
VDVAD to specific inhibition of caspase-2. To our knowledge this
is the first study that demonstrates significant RGC protection
using the pharmacological z-VDVAD inhibitor and suggests that
despite these inhibitors showing some promiscuity, z-VDVAD in
this case specifically inhibited caspase-2.
Although caspase-2 is structurally similar to an initiator caspase,
its predicted cleavage specificity resembles that of the effector
caspase-3 [46]. Caspase-2 shows a multifaceted participation in
apoptosis after a variety of cellular stresses that include DNA
damage, stimulation of death receptors, heat shock, cytoskeletal
disruption and oxidative stress [27,32]. In addition, caspase-2
deficient neurons are resistant to apoptosis induced by b-amyloid
[31,32], while activation of caspase-2 occurs in hippocampal
neurons after transient global ischemia [47]. Moreover, caspase-2
is expressed in the RGC of ischemic retinae and the reported
neuroprotective effect of intravitreal BDNF administration was
associated with diminished caspase-2 immunoreactivity [34,35].
Given this body of evidence for the involvement of caspase-2 in
RGC apoptosis, the results of our previous [7] and current studies
suggest that RGC death is orchestrated directly by caspase-2 after
ON injury, a proposition that is supported by the observed
absence of caspase-3 in RGC [7]. Similarly, few RGC were
immunopositive for C-CASP6 and C-CASP8 (VV and ZA,
unpublished observations), while no significant changes in the
levels of C-CASP6 and C-CASP8 were observed after z-VDVAD
treatment. Furthermore, significant RGC protection was observed
in our current study after caspase-2 inhibition with z-VDVAD
treatment without significant reductions in other potential effector
caspases such as caspase-3 and -7.
Caspase-2 inhibition does not promote RGC axon
regeneration
Although there are early reports that caspase inhibition does not
prevent axon degeneration [48,49], recent evidence shows
otherwise. For example, caspase-6 has been implicated as a
downstream regulator of axon degeneration initiated by p75NTR
and b-amyloid precursor protein and death receptor 6 [50,51],
while inhibition of caspase-6 and -8 promotes RGC axon
regeneration after ON injury [16]. This latter observation has
been explained by demonstrations that caspase-6 predominantly
degrades nuclear and cytoskeletal components and triggers
microtubule destabilization [24,52,53] which may contribute to
the failure of RGC axon regeneration [53]. Similarly, caspase-8
acts on molecules that regulate cytoskeletal dynamics, including
p21-activated kinase (PAK) [54] and Rho-associated protein
kinase (ROCK) [55], and may therefore contribute to the failure
of RGC axon regeneration [53]. However, we did not observe
RGC axon regeneration after intravitreal delivery of z-VDVAD
caspase-2 inhibitor, suggesting that caspase-2 does not interact
with components of the signalling cascades in which caspase-6 and
-8 regulates cytoskeletal dynamics.
In conclusion, our results demonstrate that caspase-2: (1), plays
a critical role in RGC apoptosis and that inhibition of caspase-2
significantly rescues RGC from death; (2), triggers RGC apoptosis
in a manner that is distinct to that elicited by caspase-6 or -8; and
(3), protects RGC from apoptosis after visual trauma and injury,
including glaucoma [56] and optic neuropathies [57]. These
results imply that targeting caspase-2 activation may be a useful
therapeutic in the fight against diseases in which RGC are
specifically lost, e.g. glaucoma, optic nerve injury and optic
neuritis.
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